News for Akero Therapeutics Inc Stock (AKRO)

AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit

PRNewsWire • 06/21/24

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

GlobeNewsWire • 06/21/24

INVESTOR DEADLINE TUESDAY: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO

Accesswire • 06/21/24

AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

Accesswire • 06/21/24

Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Accesswire • 06/20/24

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO

GlobeNewsWire • 06/20/24

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

GlobeNewsWire • 06/20/24

TUESDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO

GlobeNewsWire • 06/20/24

AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

GlobeNewsWire • 06/20/24

Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Accesswire • 06/19/24

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

GlobeNewsWire • 06/19/24

INVESTOR DEADLINE NEXT WEEK: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO

Accesswire • 06/19/24

Deadline in 7 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

GlobeNewsWire • 06/18/24

IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit

Accesswire • 06/18/24

Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

GlobeNewsWire • 06/17/24

Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, LLP

PRNewsWire • 06/17/24

UPCOMING INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO

GlobeNewsWire • 06/17/24

UPCOMING AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!

Accesswire • 06/17/24

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewsWire • 06/16/24

UPCOMING AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit

Accesswire • 06/16/24

AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewsWire • 06/13/24

AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!

Accesswire • 06/12/24

AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Accesswire • 06/11/24

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

GlobeNewsWire • 06/11/24

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

GlobeNewsWire • 06/11/24